CLOs on the Move

Ideaya Biosciences

www.ideayabio.com

 
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ideayabio.com
  • 7000 Shoreline Court Suite 350
    South San Francisco, CA USA 94080
  • Phone: 650.443.6209

Executives

Name Title Contact Details
Jason Throne
Vice President and General Counsel Profile
Paul Stone
Senior Vice President and General Counsel Profile
Paul Stone
Chief Financial Officer and General Counsel Profile

Similar Companies

Norgren Systems

Norgren Systems is a Ronceverte, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.

Readcoor

ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.

Innovate Biopharmaceuticals

Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.